Durability of Humoral and Cellular Immunity after an Extended Primary Series with Heterologous Inactivated SARS-CoV-2 Prime-Boost and ChAdOx1 nCoV-19 in Dialysis Patients (ICON3)

The durability of a three-dose extended primary series of COVID-9 vaccine in dialysis patients remains unknown. Here, we assessed dynamic changes in SARS-CoV-2-specific humoral and cell-mediated immunity at baseline, 3 months, and 6 months after the extended primary series in 29 hemodialyzed (HD), 2...

Descripción completa

Detalles Bibliográficos
Autores principales: Boongird, Sarinya, Setthaudom, Chavachol, Kitpermkiat, Rungthiwa, Prasongtanakij, Somsak, Srisala, Supanart, Chuengsaman, Piyatida, Nongnuch, Arkom, Assanatham, Montira, Kiertiburanakul, Sasisopin, Malathum, Kumthorn, Phuphuakrat, Angsana, Bruminhent, Jackrapong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9323398/
https://www.ncbi.nlm.nih.gov/pubmed/35891228
http://dx.doi.org/10.3390/vaccines10071064

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9323398/
https://www.ncbi.nlm.nih.gov/pubmed/35891228
http://dx.doi.org/10.3390/vaccines10071064

Ejemplares similares